Our studies suggest that p38α MAPK-dependent SERT regulatory mechanisms may harbor risk determinants for mood disorders and targeting these pathways could provide a novel route to therapeutics, one that buffers against inappropriate SERT activation versus the current strategy of totally eliminating SERT-mediated 5-HT clearance. The gene discussed is SLC6A4; the disease is mood disorder.